Overview
Renal Cell Carcinoma: Advances Across the Treatment Continuum
CustomED
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start ActivityCME/CE is no longer available for this activity
This robust, online content repository powered by CustomED™ was developed for clinicians who prefer the flexibility of self-selecting areas of interest to receive targeted CME that meets their learning goals. It offers a comprehensive review of renal cell carcinoma and recent clinical advances in treatment. Topics covered include biomarkers, immunotherapy, targeted therapies, and emerging therapies, as well as strategies for the selection of therapy and management of adverse events arising from treatment.
Create Your Own CME program in 3 easy steps:
1. Select topics of interest
2. Customize a slide deck
3. Download or participate online
This activity is intended for medical oncologists, urologist oncologists, surgeons and other healthcare professionals involved in the care or treatment of patients with RCC such as oncology nurses, nurse practitioners, and physician assistants.
• Improved knowledge of current mechanisms of action of immunotherapeutic agents and how they apply to the treatment of RCC in terms of rationale.
• Increased confidence in use of immunotherapies for RCC and utilization of relevant combination regimens in appropriate patients as part of their overall treatment to improve outcomes in patients with RCC.
• Improved understanding of the need to identify the range of irAEs, and improved knowledge of how irAEs differ from side effects associated with traditional chemotherapy.
• Increased confidence in use of immunotherapies for RCC and utilization of relevant combination regimens in appropriate patients as part of their overall treatment to improve outcomes in patients with RCC.
• Improved understanding of the need to identify the range of irAEs, and improved knowledge of how irAEs differ from side effects associated with traditional chemotherapy.
At the conclusion of this educational activity, the participant should be able to:
• Compare and contrast evidence from immunotherapy clinical trials to assess how newly approved and emerging immunotherapies improve treatment of RCC, including combination anti-VEGF and immunotherapeutic platforms (Knowledge, Competence)
• Discuss clinical factors when immunotherapy or combination immunotherapy should be considered as a treatment option for patients with RCC, such as patient selection, optimal drug combinations, and treatment sequence (Knowledge, Competence, Performance)
• Review clinical strategies for the early detection and management of immunotherapy and immunotherapy combination related adverse events in RCC patients and management plans to help mitigate them (Knowledge, Competence, Performance)
• Compare and contrast evidence from immunotherapy clinical trials to assess how newly approved and emerging immunotherapies improve treatment of RCC, including combination anti-VEGF and immunotherapeutic platforms (Knowledge, Competence)
• Discuss clinical factors when immunotherapy or combination immunotherapy should be considered as a treatment option for patients with RCC, such as patient selection, optimal drug combinations, and treatment sequence (Knowledge, Competence, Performance)
• Review clinical strategies for the early detection and management of immunotherapy and immunotherapy combination related adverse events in RCC patients and management plans to help mitigate them (Knowledge, Competence, Performance)
Supported by an educational grant from Pfizer and EMD Serono.
Nizar M. Tannir, MD, FACP (Chairperson)
Professor and Chair ad interim
Ransom Horne Jr. Professor for Cancer Research
Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Professor and Chair ad interim
Ransom Horne Jr. Professor for Cancer Research
Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
David F. McDermott MD
Professor of Medicine
Harvard Medical School
Chief, Medical Oncology
Cancer Center and Rosenberg Clinical Cancer Center
Co-Director Immunotherapy Institute
Director, Cutaneous and Immuno-Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Robert J. Motzer, MD
Kidney Cancer Section Head
Genitourinary Oncology Service
Jack and Dorothy Byrne Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center
Brian I. Rini, MD, FACP
Professor of Medicine
Division of Hematology and Oncology
Chief of Clinical Trials
Vanderbilt -Ingram Cancer Center
Lecture/Didactic • Case study • Panel discussion • Pre-/Post-Test • Other: Online toolkit will use polling questions